An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

In recent years, the U.S. Food and Drug Administration (FDA) has approved a wave of new therapies, including gene therapies, ...

Clinical trials are underway across Europe testing whether psychedelic-assisted therapies can help address mental health ...

The Cambridge, England-based drugmaker, through its rare disease unit Alexion, said final results from the long-term extension of the phase III Champion-NMOSD trial showed zero relapses in patients ...

Roche Holding AG's acquisition of 89bio, Inc. to expand cardiometabolic offerings and drive growth beyond GLP-1. Click for ...

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK ...